Cleveland Biolabs

Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications, with a focus on oncology and tissue protection. The company pursues the research, development, and commercialization of proprietary products that have the potential to treat cancer, prevent, and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Cleveland BioLabs was established in 2003 and is headquartered in Buffalo, New York.

Alexander Shakhov

Director

2 past transactions

Panacela Labs

Series B in 2015
Panacela Labs, Inc. is a joint venture company founded in 2011 by Cleveland BioLabs (Nasdaq:CBLI), a clinical-stage biotechnology company with a focus on oncology and orphan drug development, and Open Joint Stock Company “RUSNANO”, the largest Russian investment company, in collaboration with Roswell Park Cancer Institute, Children’s Cancer Institute of Australia and Cleveland Clinic Foundation. Panacela Labs is 54.6% owned by Cleveland BioLabs. Panacela Labs has residency in the Innovation Center "Skolkovo".

Panacela Labs

Series A in 2011
Panacela Labs, Inc. is a joint venture company founded in 2011 by Cleveland BioLabs (Nasdaq:CBLI), a clinical-stage biotechnology company with a focus on oncology and orphan drug development, and Open Joint Stock Company “RUSNANO”, the largest Russian investment company, in collaboration with Roswell Park Cancer Institute, Children’s Cancer Institute of Australia and Cleveland Clinic Foundation. Panacela Labs is 54.6% owned by Cleveland BioLabs. Panacela Labs has residency in the Innovation Center "Skolkovo".
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.